These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 37425383)

  • 21. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.
    Tham YC; Li X; Wong TY; Quigley HA; Aung T; Cheng CY
    Ophthalmology; 2014 Nov; 121(11):2081-90. PubMed ID: 24974815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
    Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.
    Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1757-64. PubMed ID: 20437244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer.
    Hess LM; Saboda K; Malone DC; Salasche S; Warneke J; Alberts DS
    Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2579-83. PubMed ID: 16284381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol -- a randomized controlled trial and a replacement study.
    Francis BA; Du LT; Berke S; Ehrenhaus M; Minckler DS;
    J Clin Pharm Ther; 2004 Aug; 29(4):375-80. PubMed ID: 15271105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
    Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
    Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of dorzolamide-timolol combination versus the concomitant drugs.
    Choudhri S; Wand M; Shields MB
    Am J Ophthalmol; 2000 Dec; 130(6):832-3. PubMed ID: 11124307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
    Boyle JE; Ghosh K; Gieser DK; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group.
    Hutzelmann J; Owens S; Shedden A; Adamsons I; Vargas E
    Br J Ophthalmol; 1998 Nov; 82(11):1249-53. PubMed ID: 9924327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials.
    He M; Wang W; Huang W
    PLoS One; 2013; 8(12):e83606. PubMed ID: 24349536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
    Ormrod D; McClellan K
    Drugs Aging; 2000 Dec; 17(6):477-96. PubMed ID: 11200308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing the Effectiveness and Adherence between Fixed and Non-Fixed Dorzolamide/Timolol Maleate in Open-Angle Glaucoma Patients in Hospital Universiti Sains Malaysia.
    Rasid NK; Gurusamy SM; Ahmad Tajuddin LS; Yaakub A
    Malays J Med Sci; 2023 Jun; 30(3):103-111. PubMed ID: 37425383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.